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Abstract
Kaposi’s sarcoma (KS)-associated herpesvirus (KSHV) is etiologically associated with KS, the most common AIDS-related
malignancy. KS is characterized by vast angiogenesis and hyperproliferative spindle cells. We have previously reported that
HIV-1 Tat can trigger KSHV reactivation and accelerate Kaposin A-induced tumorigenesis. Here, we explored Tat promotion
of KSHV vIL-6-induced angiogenesis and tumorigenesis. Tat promotes vIL-6-induced cell proliferation, cellular
transformation, vascular tube formation and VEGF production in culture. Tat enhances vIL-6-induced angiogenesis and
tumorigenesis of fibroblasts and human endothelial cells in a chicken chorioallantoic membrane (CAM) model. In an
allograft model, Tat promotes vIL-6-induced tumorigenesis and expression of CD31, CD34, SMA, VEGF, b-FGF, and cyclin D1.
Mechanistic studies indicated Tat activates PI3K and AKT, and inactivates PTEN and GSK-3b in vIL-6 expressing cells.
LY294002, a specific inhibitor of PI3K, effectively impaired Tat’s promotion of vIL-6-induced tumorigenesis. Together, these
results provide the first evidence that Tat might contribute to KS pathogenesis by synergizing with vIL-6, and identify PI3K/
AKT pathway as a potential therapeutic target in AIDS-related KS patients.
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Introduction
Kaposi’s sarcoma-associated herpesvirus (KSHV), also known
as human herpesvirus 8 (HHV-8), is a c2-herpesvirus. KSHV is
linked to the development of Kaposi’s sarcoma (KS) [1], primary
effusion lymphoma (PEL) and multicentric Castleman’s disease
(MCD) [2]. KS is a vascular neoplasm of proliferative endothelial
spindle cells. KS tumors contain abnormal and leaky vessels and
extravasated red blood cells with haemosiderin deposits [3].
Although KSHV infection is necessary for the development of
KS, it is not sufficient. The most important cofactor that
contributes to KS development is HIV coinfection. The incidence
of KS is 1 in 100,000 in the general population, but it is increased
to 1 in 20 in HIV-infected individuals [4], and 1 in 3 in HIV-
infected homosexual men before the introduction of HAART [5].
Higher KSHV infection rates and HIV-induced immune
deficiency contribute to the higher KS incidence in the HIV
population but they are likely not the only contributing factors.
Previous studies have shown that KS are almost exclusively seen in
HIV-1- but not HIV-2-infected individuals in Gambia, West
Africa, despite similar KSHV infection rates and degree of
immunodeficiency in both groups. Furthermore, KS often occurs
early in AIDS, prior to the onset of severe immunosuppression.
Additionally, AIDS-related KS (AIDS-KS) is more aggressive,
disseminated, and resistant to treatment than iatrogenic KS.
Therefore, additional factors could influence the development of
AIDS-KS including secreted HIV-1 proteins, particularly Tat.
Although HIV-1 does not infect KS tumor cells, studies have
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shown that Tat is readily detected in spindle cells of AIDS-KS
lesions and promotes the growth of KS-derived endothelial cells
(known as KS progenitor cells), thus might play a crucial role in
the initiation and progression of KS in AIDS patients [6–8]. Our
recent studies have revealed that Tat can not only activate lytic
replication of KSHV by regulating the JAK/STAT signaling
pathway [9], but also accelerate KSHV Kaposin A-induced cell
proliferation and tumorigenesis [10].
KSHV encodes more than 90 genes and 25 mature miRNAs
[11], many of which possess oncogenic properties [12]. Among
them, vIL-6 encoded by ORF K2 is a homologue of cellular IL-6.
Studies have demonstrated that vIL-6 can promote cellular
proliferation, cell survival, and extrahepatic acute-phase response
by stimulating several signaling pathways. vIL-6 engages the
gp130 receptor but not the IL-6 receptor gp80 [13]. Furthermore,
vIL-6 is expressed in 2,5% PEL cells and 5,25% B cells
surrounding the follicular centers of MCD [2]. vIL-6 also
contributes to KSHV immune evasion by inhibiting IFN-a-
induced antiviral response [14]. In addition, vIL-6 can induce the
secretion of cellular IL-6 and VEGF to promote cell proliferation
of IL-6-depentent cell growth, and is required for hematopoiesis,
angiogenensis and tumorigenesis [2,15].
Although the mechanisms of KS pathogenesis by KSHV have
not been fully clarified, several lines of evidence supported that the
vGPCR plays a key role in KS initiation and progression. Recent
studies have reported that PI3Kc, a PI3K isoform exhibiting
preferential expression in certain cell types such as endothelial cells
(ECs), is strictly essential for vGPCR induction of AKT/mTOR
signaling and sarcomagenensis [16]. Interestingly, by inducing
activation of NF-AT and NF-kB, Tat accelerates vGPCR-induced
tumorigenesis [17]. These observations have prompted to further
investigate the interactions of Tat with other KSHV proteins.
In this study, we have revealed that HIV-1 Tat promotes vIL-6-
induced angiogenesis and tumorigenesis in both chicken chorio-
allantoic membranes (CAM) model and an allograft model. We
have shown that PI3K/PTEN/AKT/GSK-3b signaling is an
essential pathway that mediates the process.
Materials and Methods
Ethics Statement
Animal care and handling conformed to the Guide for Care and
Use of Laboratory Animals published by the US National
Institutes of Health, and the study was approved by Nanjing
Medical University’s ethical committee.
Cells, Plasmids, Transfection and Reagents
NIH3T3, HEK293T and EA.hy926 cells were cultured as
described previously [10,18]. To express KSHV-vIL-6 in
EA.hy926 and NIH3T3 cells, a 615-bp fragment of vIL-6 cDNA
was amplified from BCBL-1 cells by PCR [15] and inserted into
the pcDNA3.1 plasmid (Invitrogen Inc, Carlsbad, CA), named
pK2-Flag. The overexpression plasmid PTEN cDNA construct
(pPTEN) and the GSK-3b mutant plasmid GSK-3b-S9A (pS9A)
were described previously [19]. The dominant-negative PI3K
construct (PI3K-DN) and dominant-negative AKT construct
(AKT-DN) were described elsewhere [19,20]. The KSHV vIL-6
luciferase reporter construct (pvIL-6-Luc), which contains a 3.2-kb
promoter region upstream of the methionine initiation codon of
the vIL-6 gene, and RTA-expressing plasimid pcDNA-RTA were
described previously [21,22]. The plasmid pTZIII-CAT express-
ing the chloramphenicol acetyltransferase (CAT) enzyme under
the control of the HIV-1 long terminal repeat (LTR) was described
previously [9]. Transfections of EA.hy926 cells were performed
with Effectence transfection reagent (Qiagen) and the other cells
with Lipofectamine 2000 reagent (Invitrogen) according to the
manufacturer’s instruction. The specific inhibitor of PI3K,
LY294002, was purchased from Sigma (St. Louis, MO, USA).
Recombinant full length HIV-1 Tat protein (101 amino acids) was
purchased from Abcam (Cambridge, MA, USA).
Generation of Stable Transfectants Expressing KSHV vIL-6
The study design is exhibited in Fig. S1. Briefly, to generate vIL-
6-expressing KS-like tumor cell transfectant, the expression
plasmid of pK2-Flag was transfected into NIH3T3 cells and the
pcDNA3.1 vector was transfected for a negative control. The
stable clones were obtained through selection by G418. Next,
stable transfectant cells (56106 cells per 100 ml of PBS per animal)
were injected subcutaneously (s.c.) into the left flank of male
athymic BALB/c nu/nu mice. After four weeks, tumor tissue was
detached, digested by trypsin and collagenase type 2 (Sigma) to
obtain primary KS-like tumor cells. The primary cells were
selected with G418 followed by end-point limiting dilution assay to
acquire individual cell clones. The expression of vIL-6 mRNA and
protein in primary tumor cell clones was detected by RT-PCR and
Western blot, respectively. Finally, twelve stable transfectants were
obtained; representative clones 4E3, 3D10, and the negative
control T/V were used in this study.
Besides NIH3T3-derived KS-like tumor transfectant, endothe-
lial cell (EC)-derived transfectant was also generated. As shown in
Fig. S1, pK2-Flag was transfected into endothelial cells and the
vector of pcDNA3.1 for a negative control. The individual stable
clones were obtained through selection by G418 followed by end-
point limiting dilution assay. Six stable transfectants were obtained
by RT-PCR and Western blot; representative clones E6, F7, and
the negative control E/V were used in this study.
Lentiviral Tat Production and Transduction
The lentiviral plasmid system, the self-inactivating pHAGE-
CMV-MCS-IzsGreen transferring plasmid, was used in this study.
It was used to generate vesicular stomatitis virus (VSV)-
pseudotyped lentiviral Tat, which would produce the full-length
Tat101 of HIV-1[9]. A deletion mutant of Tat (gTat), Tatg21–
68, was also synthesized as a control. Tatg21–68 lacks both the
cysteine-rich region of Tat, which is defective for transactivation of
the HIV-1 long terminal repeat, and the induction region of
neovascularization [23,24]. The virus-packaging cells 293T
(16106) were seeded in a 10-cm dish one day before transfection
with pHAGE-Tat, packaging vector psPAX2 and envelope vector
pMD2.G. Forty-eight hours after transfection, the virus containing
supernatant was collected. The virus titres were determined on
293T to be about 26107 to 26108 transducing units (TU)/mL.
The recombinant lentivirus full-length Tat, the deletion mutant of
Tat and their vector control were designated as Tat, gTat and
Mock in this study, respectively.
Cell Proliferation Assay
Cell proliferation was examined by MTT assays according to
standard methods.
CAT Assay
CAT assay was performed as described previously [9].
Soft Agar Assay
Soft agar assay was performed as described previously [10].
Briefly, cell suspensions containing 0.3% agar were seeded in each
well of 12-well plates containing an underlay of 0.6% agar in
AKT Signal Controls Angiogenesis by Tat and vIL-6
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complete medium. Cultures were supplemented with complete
medium per week and colonies were scored 14 to 21 days after
seeding the cells.
Microtubule Formation in Matrigel
Microtubule formation assay was performed on endothelial cells
with the conditioned medium from 4E3 and T/V cells transduced
by MOI 10 of lentivirus Tat or Mock for 48 hours as described
previously [25].
Chicken Chorioallantoic Membrane (CAM) Assay
White Leghorn fertilized chicken eggs were incubated at 37uC
under constant humidity. To investigate the effect of Tat protein
on KSHV vIL-6-induced angiogenesis, stable transfectant cells or
cells isolated from induced tumor (56105 cells ) with or without
transfection prior to transduction by MOI 10 of Tat or Mock were
mixed at 1:1 ratio with Matrigel and implanted onto the
chorioallantoic membranes (CAM) of chicken embryo at day 9.
Tumor angiogenesis and tumor growth were analyzed 4 to 5 days
after the implantation. The number and extent of branching of
blood vessels were scored as relative angiogenesis index by two
observers in a double-blind manner. The representative tumors
were photographed.
Tumorigenicity Assay in Nude Mice
The tumorigenic potential of stable transfectant with or without
treatments was tested in 3- to 4-week-old male athymic BALB/c
nu/nu mice (Shanghai Slac Laboratory Animal Center, Shanghai,
China) housed under specific pathogen-free conditions. Cells
(36106 cells per 100 ml of PBS per animal) were injected
subcutaneously (s.c.) into the left flank. Five mice were used in
each group, and experiments were performed twice. Tumor size
was estimated by two-dimensional caliper measurement. For
tumor allograft experiments, 4E3 cells transduced with Tat or
Mock were injected s.c. into right flank of each mouse. When
allografts reached volumes of 100 mm3 (about 10 days post-
injection), the mice of Tat and Mock groups showing tumors were
randomly split into a Mock+DMSO group, a Tat+DMSO group,
a Mock+LY294002 group, and a Tat+LY294002 group. Accord-
ingly, the groups were administered with either solvent control
(DMSO) or LY294002 (25 mg/kg) by intraperitoneal injections (5
times, once for every two days).
Western Blot and Antibodies
Western blot was performed as previously described [9]. Anti-
VEGF (A20) rabbit polyclonal antibody (pAb), anti-basic FGF (b-
FGF) rabbit pAb, anti-b-Actin mouse monoclonal antibody (mAb),
anti-a-Tubulin mouse mAb, and horseradish peroxidase (HRP)-
conjugated goat anti-mouse and rabbit IgG were purchased from
Santa Cruz Biotechnologies (Santa Cruz, CA). Anti-Flag rabbit
pAb, anti-cyclin D1 rabbit mAb, anti-phospho-PTEN (Ser380)
rabbit pAb, anti-PTEN rabbit pAb, anti-phospho-PI3K
[p85(Tyr458)/p55(Tyr199)] rabbit pAb, anti-PI3K rabbit pAb,
anti-phospho-AKT (Ser473) mouse mAb, anti-AKT mouse mAb,
anti-phospho-GSK-3b (Ser9) rabbit pAb, anti-GSK-3b rabbit
pAb, anti-CD31 and CD34 mouse mAbs were obtained from Cell
Signaling Technologies (Danvers, MA). Anti-smooth muscle actin
(SMA) rabbit pAb were purchased from AbbiotecTM (San Diego,
CA).
Luciferase Reporter Assay
Luciferase reporter assay was performed as described previously
[26].
Immunohistochemistry
Informative sections of frozen or formalin-fixed, paraffin-
embedded tumor from CAM or nude mice were immunostained
as previously described [10]. Formalin-fixed paraffin-embedded
tissue samples from one patient diagnosed with KS at the First
Affiliated Hospital of Nanjing Medical University were obtained
from the pathology archives for immunohistochemical studies.
Statistical Analysis
All experiments were performed at least in triplicate if not
mentioned. Numerical data were expressed as mean 6 SD. Two
group comparisons were analyzed by two-sided Student’s t-test. P
values were calculated, and P,0.05 was considered significant.
Results
Tat Promotes Cell Proliferation and Vascular Tube
Formation of vIL-6-expressing Fibroblasts and
Endothelial Cells
KSHV vIL-6 induces angiogenesis and tumorigenesis when
expressed in NIH3T3 cells [15]. We used 2 representative stable
clones 4E3, 3D10 of vIL-6-transformed NIH3T3 tumor cells from
the vIL-6-expressing tumors and 2 representative clones E6, F7 of
vIL-6 expressing human endothelial cells in this study (Fig. S1). To
investigate the interaction of vIL-6 with Tat, we transduced the
cells with a lentivirus expressing Tat. Western blot showed that the
expression level of Tat increased with MOI (Fig. 1A) without
inducing apparent apoptosis and cell death (data not shown). As
expected, vIL-6 was robustly expressed in both 4E3 and E6 clones
but was not affected by Tat expression.
We examined the effect of Tat on the proliferation of vIL-6-
expressing cells using MTT assay. vIL-6-expressing cells 4E3 and
3D10 had higher proliferation rates compared to Mock cells
(Fig. 1B). Expression of Tat further accelerated the proliferation of
4E3 and 3D10 cells. As expected, expression of Tat alone
increased cell proliferation. Similarly, vIL-6 expressing endothelial
cells E6 and F7 had higher proliferation rates compared to Mock
cells (Fig. 1C). Expression of Tat further increased the proliferation
of E6 and F7 cells. We next examined the effect of soluble Tat on
the proliferation of vIL-6-expressing cells. Consistent with these
results, soluble Tat accelerated the proliferation of vIL-6-
expressing fibroblasts and endothelial cells (Fig. 1D and 1E), while
it was functional in CAT assay (Fig. S2A and S2B). In soft agar
assay, the number of colony formation of Tat-transduced 4E3 cells
was significantly higher than that of Mock-transduced 4E3 cells
(p,0.001) and Tat-transduced T/V cells (p,0.001), respectively
(Fig. 2A). The similar results were also observed in vIL-6 and Tat
co-expressing endothelial cells in plate colony assay (Fig. 2B),
indicating that Tat enhanced vIL-6 cellular transformation
potential. To examine the effect of Tat on vIL-6-induced
angiogenesis, we performed tube formation assay. As shown in
Fig. 2C, the tube formation of Tat-transduced 4E3 cells was
significantly increased compared with those of both Mock-
transduced 4E3 cells (p = 0.018) and Tat-transduced T/V control
cells (p = 0.011). Examination of VEGF expression showed that
the level of VEGF was correlated with the tube formation ability of
the cells (Fig. 2D). Taken together, these data indicate that Tat
promotes cell proliferation, cellular transformation and vascular
tube formation of vIL-6-expressing cells.
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Tat Enhances vIL-6-induced Angiogenesis and
Tumorigenesis
We examined the effect of Tat on vIL-6-induced angiogenesis
and tumorigenesis in the CAM model. 4E3 and T/V control cells
were transduced by Tat or Mock and implanted onto the CAM.
The angiogenesis index of Tat-transduced 4E3 cells increased
significantly while compared with those of both Mock-transduced
4E3 cells (p = 0.006) and Tat-transduced T/V cells (p = 0.007)
(Fig. 3A and 3C). Similarly, tumorigenesis ability of 4E3 cells was
augmented by Tat compared with 4E3 cells transduced by Mock
(p = 0.003) and T/V cells transduced by Tat (p = 0.001) (Fig. 3B
and 3D). As expected, expression of Tatg21–68 alone did not
increase the angiogenesis index or the growth rate of the tumor
compared to Mock cells; and co-expression of Tatg21–68 and
vIL-6 did not further increase angiogenesis and tumorigenesis. We
next examined the effect of soluble Tat on vIL-6-induced
Figure 1. Tat promotes the proliferation of vIL-6 expressing cells. (A) Western blot analysis of Flag tagged vIL-6 and Tat expression in 4E3
and E6 cells transduced by different MOI of lentiviral Tat. (B) MTT assay for the proliferation of fibroblasts derived 4E3, 3D10 and control T/V cells and
(C) endothelial cells derived E6, F7 and control E/V cells transduced by MOI 10 of Tat at days 2 to 8 post-transduction. The results represent the mean
6 SD; shown is one representative experiment performed in triplicate. (D) MTT assay for the proliferation of fibroblasts derived 4E3, 3D10 and control
T/V cells and (E) endothelial cells derived E6, F7 and control T/V cells stimulated with the soluble Tat (300 ng/mL) at days 1 to 3 post-treatment.
**P,.01 and ***P,.001 for Student’s t-test versus corresponding controls, respectively.
doi:10.1371/journal.pone.0053145.g001
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angiogenesis and tumor formation. Consistent with above results,
soluble Tat further increased angiogenesis and tumorigenesis of
4E3 cells in CAM model (Fig. 3E and 3F). Because KS tumors
consist of predominantly endothelial cells [3], we employed stable
vIL-6-expressing endothelial cells E6 for examination. Similar to
fibroblasts, angiogenesis ability of Tat-transduced E6 cells
increased significantly compared with those of both Mock-
transduced E6 cells (p,0.001) and Tat-transduced E/V control
cells (p = 0.001) (Fig. 3G). On the other hand, tumorigenesis ability
of Tat-transduced E6 cells was augmented significantly compared
with those of both Mock-transduced E6 cells (p = 0.009) and Tat-
transduced E/V control cells (p = 0.032) (Fig. 3H).
H&E staining showed that tumors derived from the vIL-6
expressing cells were characterized by neovascularization, and
various sizes and irregular shapes of hemorrhagic foci (Fig. 3I).
These features were markedly enhanced in tumors derived from
cells expressing both vIL-6 and Tat. Immunohistochemical
staining showed increased expression levels of VEGF, b-FGF,
and cyclin D1 in tumors from the Tat- and vIL-6-expressing cells,
which were further enhanced in tumors from cells expressing both
Tat and vIL-6 (Fig. S3A). These observations collectively
demonstrated that Tat enhances vIL-6-induced angiogenesis and
tumorigenesis of fibroblasts and endothelial cells.
Tat Promotes vIL-6-induced Angiogenesis and
Tumorigenesis by Regulating the PI3K/PTEN/AKT/GSK-3b
Pathway
Because Tat is a trans activative transcription protein, we
reasoned that it might influence vIL-6 transcription. Luciferase
report assay was performed. We found that Tat failed to affect the
promoter activity of vIL-6 either with or without expression of
KSHV RTA (Fig. 4A), which was consistent with the above
observation in vIL-6 protein expression (Fig. 1A). To dissect the
mechanism of Tat promotion of vIL-6-induced angiogenesis and
tumorigenesis, we further examined the PI3K/PTEN/AKT/
GSK-3b signaling pathway. Consistent with the observed pheno-
types, we found that expression of Tat or vIL-6 alone increased the
phosphorylated forms of PTEN, PI3K, AKT, and GSK-3b in
NIH3T3 cells (Fig. 4B). Expression of both Tat and vIL-6 further
increased the levels of phosphorylated forms of these proteins. Of
interest, the level of total PTEN was reduced in cells expressing
Figure 2. Tat promotes the transformation potential, microtube formation and VEGF production of vIL-6 expressing cells. (A) Soft
agar analysis of the colony formation of 4E3 and control T/V cells and (B) plate colony formation assay for E6 and control E/V cells transduced by MOI
10 of Tat or Mock after two weeks. Photographs depict the colony formation (top; original magnification,6100). The bars in the graph represent the
mean 6 SD; shown is one representative experiment of three performed (bottom). (C) Matrigel assay analysis of microtube formation. The
photographs depict the microtubules after 6 hours of incubation (top; original magnification,6100) and the quantified results represent the mean6
SD (bottom). (D) VEGF expression was analyzed by Western blot in 4E3 and T/V cells transduced by MOI 10 of Tat or Mock. The relative level of VEGF
was determined by quantitative densitometry compared to actin. The relative value of VEGF in the T/V+Mock group was considered to be 1 for
comparison.
doi:10.1371/journal.pone.0053145.g002
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Figure 3. Tat enhances vIL-6-induced angiogenesis and tumorigenesis in the CAMmodel. (A) Tat enhances angiogenesis of 4E3 cells. 4E3
cells were transduced by lentiviral Tat, gTat or Mock for 24 hours. Collected cells were mixed with matrigel and subsequently implanted onto the
CAM (the detailed procedure seen in Methods). The representative angiogenic pictures and the quantification of blood vessels (C) on the CAM were
shown. The number of blood vessels was normalized to that of Matrigel alone, and the results were expressed as the mean 6 SD (n = 5 to 7). Two
independent experiments were performed with similar results. (B) Tat enhances tumorigenesis of 4E3 cells. The representative tumor pictures and the
quantification of tumor weight (D) on the CAM were shown. The tumor weight was normalized to that of Matrigel alone and the data represents the
mean 6 SD (n = 5 to 7). (E) Soluble Tat enhances angiogenesis and tumorigenesis (F) of 4E3 cells. The number of blood vessels was normalized to
that of Matrigel alone, and the results were expressed as the mean 6 SD (n = 6). (G) Tat promotes angiogenesis and tumorigenesis (H) of E6 cells. E6
cells were transduced by lentiviral Tat or Mock for 24 hours and implanted onto CAM. The tumor weight and number of blood vessels were
AKT Signal Controls Angiogenesis by Tat and vIL-6
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Tat or vIL-6. Upregulation of phosphorylated AKT and GSK-3b
was also observed in tumors (Fig. 4C).
We further determined whether Tat enhanced vIL-6-induced
angiogenesis and tumorigenesis is regulated by the PI3K/PTEN/
AKT/GSK-3b pathway. Expression of a dominant negative
mutant of PI3K completely inhibited Tat-mediated enhancement
of angiogenesis and tumorigenesis (Fig. 5A and 5B). Similar results
were also observed with a dominant negative mutant of AKT
(Fig. 5C and 5D). As expected, inhibition of PI3K resulted in the
reduction of phosphorylated forms of AKT and GSK-3b, both of
which are downstream of PI3K (Fig. 5E). Inhibition of AKT
resulted in the reduction of phosphorylated forms of GSK-3b,
which is downstream of AKT (Fig. 5F). Histologically, inhibition of
AKT not only decreased the tumor features including hemor-
rhagic foci and neovascularization (Fig. S3B), but also reduced the
levels of VEGF, b-FGF, and cyclin D1 (Fig. S3C).
We further confirmed the above observations in endothelial
cells. Similar to the results in Fig. 5C and 5D, the quantification of
both blood vessels and tumor weight showed that inhibition of
AKT activity suppressed the promoting effect of Tat on vIL-6-
induced angiogenesis and tumorigenesis of endothelial cells in the
CAM model (Fig. 5G, 5H, 5I, 5J).
Because the phosphorylated PTEN was elevated in Tat-
transduced 4E3 cells (Fig. 4B), we expressed PTEN (pPTEN) in
these cells and assessed the effect on angiogenesis and tumorigen-
esis. Expression of pPTEN not only significantly inhibited Tat-
mediated enhancement of angiogenesis and tumorigenesis (Fig. 6A
and 6B) but also decreased the enhanced effect of Tat on the
phosphorylation of AKT and GSK-3b by vIL-6 (Fig. 6C). The
above results showed that activation of PI3K and AKT resulted in
the inhibition of GSK-3b (Fig. 4B and 4C) indicating that GSK-3b
might mediate Tat-induced enhancement of angiogenesis and
tumorigenesis. Indeed, expression of GSK3b-S9A (pS9A), a
GSK3b mutant, inhibited Tat-mediated enhancement of both
angiogenesis and tumorigenesis (Fig. 6D and 6E).
normalized to those of Matrigel alone, and the data was the mean 6 SD (n = 5 to 7). (I) H&E staining analysis of histological features in tumor tissues
from Tat-transduced 4E3 cells on the CAM. The representative pictures were shown (original magnification,6400). Arrows point to hemorrhagic foci.
doi:10.1371/journal.pone.0053145.g003
Figure 4. Tat augments vIL-6-induced phosphorylation of PTEN, PI3K, AKT, and GSK-3b both in vitro and in vivo. (A) Effects of Tat on
vIL-6 promoter activities in 293T cells. Cells were transfected with RTA expression plasmid (With RTA) or its control vector (Without RTA) and
subsequently cotransfected with the firefly luciferase reporter construct pvIL-6-Luc (0.4 mg) and a Renilla luciferase construct pRL-TK (0.02 mg)
following infection with Tat or Mock. Luciferase activities were measured, normalized to inner control, and presented as fold increase (n-fold). All data
points were the averages of three independent experiments performed in triplicate. (B) Phosphorylation levels of PTEN, PI3K, AKT, and GSK-3b were
analyzed by Western blot in 4E3 and T/V cells transduced by MOI 10 of Tat or Mock. Both 4E3 and T/V cells were starved with serum-free medium for
24 hours and followed by Tat or Mock transduction for 24 hours. The relative level of phosphorylation protein was determined by quantitative
densitometry after normalized to corresponding non-phosphorylation protein. The relative level of phosphorylation protein in T/V+Mock group was
considered to be 1 for comparison. (C) Phosphorylation AKT and GSK-3b in tumor tissues from 4E3 and T/V cells on the CAM were analyzed by
Western blot as above.
doi:10.1371/journal.pone.0053145.g004
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Figure 5. Tat promotes vIL-6-induced angiogenesis and tumorigenesis through activation of PI3K/AKT pathway in CAM model. (A)
Inhibition of PI3K activity suppressed the enhanced effect of Tat on vIL-6-mediated angiogenesis. 4E3 or T/V cells were transfected by the dominant-
negative PI3K construct (PI3K-DN) and its control plasmid pSG5 for 24 hours and followed by Tat or Mock transduction for another 24 hours.
Collected cells were implanted onto the CAM. The quantification of blood vessels was expressed as the mean 6 SD (n = 5 to 7). Two independent
experiments were performed with similar results. (B) Inhibition of PI3K suppressed the enhanced effect of Tat on vIL-6-mediated tumorigenesis. 4E3
or T/V cells were treated as in (A). Quantification of tumor weight was expressed as the mean6 SD (n = 5 to 6). (C) Inhibition of AKT activity restrained
the promoted effect of Tat on vIL-6-mediated angiogenesis. 4E3 cells were transfected by the AKT-DN and its control plasmid pSRa for 24 hours and
followed by Tat or Mock transduction for another 24 hours. Collected cells were implanted onto the CAM. The quantification of blood vessels was
expressed as the mean 6 SD (n = 5 to 8). (D) Inhibition of AKT restrained the promoted effect of Tat on vIL-6-mediated tumorigenesis. 4E3 cells were
treated as in (C). Quantification of tumor weight was expressed as the mean6 SD (n = 5 to 6). (E) Inhibition of PI3K abrogated the enhanced effect of
Tat on phosphorylation of AKT and GSK-3b by vIL-6. 4E3 cells were treated as in (A). Collected cells were implanted onto the CAM. The
AKT Signal Controls Angiogenesis by Tat and vIL-6
PLOS ONE | www.plosone.org 8 January 2013 | Volume 8 | Issue 1 | e53145
Together these data suggest that Tat augments vIL-6-induced
angiogenesis and tumorigenesis by activating PI3K/AKT and
inactivating PTEN and GSK-3b signals in both fibroblasts and
endothelial cells-mediated CAM model.
Activation of PI3K/AKT Pathway is Required for Tat
Promotion of vIL-6-induced Tumorigenesis
We further examined the effect of Tat on the growth of vIL-6-
induced tumors in nude mice. Expression of vIL-6 or Tat alone
moderately accelerated the growth of tumors induced by NIH3T3
cells. However, expression of both Tat and vIL-6 significantly
increased the tumor growth rates (Fig. 7A). At 33 days post-
inoculation, the average tumor weight was strikingly higher with
the Tat-transduced 4E3 cell group compared to that of by Mock-
transduced 4E3 cell group or T/V control cells transduced by Tat
alone (Fig. 7B). As expected, expression of Tatg21–68 failed to
accelerate the growth of tumors and increase the average tumor
weight by vIL-6 (Fig. 7A and 7B). Histologically, the tumor was
characterized by various sizes and irregular shapes of dense
neovascularization and hemorrhagic necrotic foci (Fig. 7C). Large
multinucleated cell infiltrations of lymphocytes were present in the
tumors. These histological features were increased in the Tat-
transduced 4E3 cell group compared to Mock-transduced 4E3 cell
group or T/V control cells transduced by Tat alone (Fig. 7C).
Immunohistochemical staining showed the expression of CD31,
CD34, SMA, VEGF, b-FGF, and cyclin D1 in tumors which were
substantially increased in Tat-transduced 4E3 cells (Fig. 7C and
7D; Fig. S4A and S4B). Western blot with extracts from the
tumors showed increased levels of phosphorylated forms of AKT
and GSK-3b in the Tat-transduced 4E3 cell group compared to
those of 4E3 cells transduced by Mock and T/V control cells
transduced by Tat (Fig. 8A), indicating the involvement of AKT
signaling in Tat-mediated promotion of vIL-6-induced tumori-
genesis. Expression of a dominant negative mutant of AKT (AKT-
DN) but not its vector control (pSRa) inhibited the progression of
the tumors of Tat-transduced 4E3 group (Fig. 8B). Examination of
phosphorylation levels of AKT and GSK-3b in tumor tissues of the CAM model were analyzed by Western blot. (F) Inhibition of AKT abolished the
promoted effect of Tat on phosphorylation of GSK-3b by vIL-6. 4E3 cells were treated as in (C). Collected cells were implanted onto the CAM. The
phosphorylation level of GSK-3b in tumor tissues of the CAM model was analyzed by Western blot. (G) Inhibition of AKT activity restrained the
promoted effect of Tat on vIL-6-mediated angiogenesis of endothelial cells. E6 cells were transfected by the AKT-DN and its control plasmid pSRa for
24 hours and followed by Tat or Mock transduction for another 24 hours. Collected cells were implanted onto the CAM. The representative
angiogenic pictures and the quantification of blood vessels (H) on the CAM were shown. (n = 6 to 8). (I) Inhibition of AKT restrained the promoted
effect of Tat on vIL-6-mediated tumorigenesis of endothelial cells. E6 cells were treated as in (G). The representative tumor pictures and the
quantification of tumor weight (J) on the CAM were shown. The tumor weight was normalized to that of Matrigel alone and the data represents the
mean 6 SD (n = 6).
doi:10.1371/journal.pone.0053145.g005
Figure 6. Tat enhances vIL-6-induced angiogenesis and tumorigenesis through inactivation of PTEN and GSK-3b signals in CAM
model. (A) Overexpression of PTEN suppressed the enhanced effect of Tat on vIL-6-mediated angiogenesis. 4E3 cells were transfected by pPTEN and
its control plasmid pcDNA for 24 hours and followed by Tat or Mock transduction for another 24 hours. Collected cells were implanted onto the CAM.
The quantification of blood vessels was expressed as the mean 6 SD (n = 5 to 8). Two independent experiments were performed with similar results.
(B) Overexpression of PTEN suppressed the enhanced effect of Tat on vIL-6-mediated angiogenesis. 4E3 cells were treated as in (A). Quantification of
tumor weight was expressed as the mean 6 SD (n = 5). (C) Overexpression of PTEN restrained the enhanced effect of Tat on phosphorylation of AKT
and GSK-3b by vIL-6. 4E3 cells were treated as in (A). Collected cells were implanted onto the CAM. The phosphorylation levels of AKT and GSK-3b in
tumor tissues of the CAM model were analyzed by Western blot. (D) Overexpression of GSK-3b decreased the promoted effect of Tat on vIL-6-
mediated angiogenesis. 4E3 cells were transfected by the pS9A and its control plasmid pcDNA for 24 hours and followed by Tat or Mock transduction
for another 24 hours. Collected cells were implanted onto the CAM. The quantification of blood vessels was expressed as the mean 6 SD (n = 5 to 8).
(E) Overexpression of GSK-3b decreased the promoted effect of Tat on vIL-6-mediated tumorigenesis. 4E3 cells were treated as in (D). Quantification
of tumor weight was expressed as the mean 6 SD (n = 5).
doi:10.1371/journal.pone.0053145.g006
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the tumor weight at day 30 post-inoculation showed that cells
expressing AKT-DN had substantially smaller tumor sizes
compared to vector control (Fig. 8C). H&E staining showed that
the numbers of newly formed vessels and scattered lymphocytes
were markedly reduced in Tat-transduced 4E3 cells expressing
AKT-DN compared to the vector control (Fig. S5A). Immuno-
histochemical staining demonstrated that the expression levels of
VEGF, b-FGF, cyclin D1, and SMA were reduced in tumors
induced by Tat-transduced 4E3 cells expressing AKT-DN
compared to vector control (Fig. S5B and S5C). As expected,
AKT-DN also reduced the level of the phosphorylated form of
GSK-3b compared to the vector control (Fig. 8D). These results
indicated that activation of AKT mediates Tat promotion of vIL-
6-induced tumorigenesis.
To determine the role of PI3K in Tat-mediated promotion of
vIL-6-induced tumors, we treated the tumor-bearing mice with
LY294002, a specific PI3K inhibitor for 5 times at the indicated
times starting on day 10 post-inoculation. Similar to AKT-DN,
LY294002 effectively inhibited the growth of the tumors induced
by Tat-transduced 4E3 cells compared to tumor-bearing mice
treated with DMSO (Fig. 8E and 8F). Taken together, these results
indicated that PI3K is an effective target for the vIL-6 and Tat-
induced tumors.
Discussion
Previous studies have shown that vIL-6 can directly bind to the
gp130 receptor on human, mouse and rat cells, thereby activating
the JAK/STAT signaling pathway. Therefore, vIL-6 mimics
biological properties of cellular IL-6, such as supporting cell
growth of the IL-6-dependent cell lines B9 or INA-6 and inducing
acute-phase gene expression in a hepatocellular carcinoma cell line
[27–30]. However, in contrast to IL-6, vIL-6 does not require the
IL-6R for receptor complex formation and signaling. Accordingly,
vIL-6 can stimulate far more cell types than IL-6 can since its
activity is not restricted to cells that express the IL-6R.
Furthermore, the vIL-6-producing NIH3T3 cells give rise to
tumors in nude mice more quickly than control cells do [15]. Here,
we revealed that vIL-6 expressing NIH3T3 cells induced vast
angiogenesis and tumorigenesis and vIL-6 also promoted angio-
genesis and tumorigenesis induced by endothelial cells in the CAM
model. Together, these results highlight the oncogenic properties
of the vIL-6 protein and its likely important role in KS
pathogenesis.
We and others have demonstrated that Tat possesses multiply
biological activities including activation of KSHV replication
[9,31], enhancement of cell proliferation [32–35], induction of
KS-like lesions [4,36], and acceleration of tumorigenesis by
vGPCR and Kaposin A [10,17]. These results suggest that Tat
plays a vital role in AIDS-KS pathogenesis, however, the
underlying molecular mechanism remains unclear. Here, our
Figure 7. Tat promotes vIL-6-induced tumorigenesis in nude mice. (A) Plot of the volume of the tumors. 4E3 and T/V cells were transduced
by Tat, gTat or Mock and injected s.c. into the left flank of nude mice. The animals were monitored every day for the appearance of tumors until 33
days. Tumor size was estimated by two-dimensional caliper measurement. The results are expressed as the mean 6 SD (n = 5). *P,.05, **P,.01 and
***P,.001 for Student’s t-test versus T/V+Tat groups, respectively. gP,.05 and ggP,.01 for Student’s t-test versus 4E3+ Mock groups, respectively.
ns, not significant, t-test. (B) Column diagram of average tumor weight. Tumor-bearing mice were killed at day 33 after injections; and tumors were
removed and weighed. Data reflect the mean 6 SD. (C) H&E staining analysis of histological features and immunohistochemical staining analysis of
the expression levels of CD31, CD34 and SMA in tumor tissues from Tat-transduced 4E3 cells in nude mice. Both human KS sample and nude tumor
samples for SMA detection were formalin-fixed and paraffin-embedded sectioned. The rest were frozen sections. The representative pictures were
shown (original magnification,6200). Arrows point to hemorrhagic foci. (D) Quantification of results in (D).
doi:10.1371/journal.pone.0053145.g007
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study, for the first time, has directly tested the effect of Tat on
angiogenesis induced by KSHV vIL-6. The synergistic effect that
we have observed is very striking. As uptake of Tat by cells is very
efficient [34,37], Tat is mostly positive in spindle cells of AIDS-KS
lesions [8], and HIV-1-infected patients often have high level of
circulating Tat [38], we believe that our observations are highly
relevant to the clinical setting.
Our results also showed that Tat did not directly increase the
expression of vIL-6, suggesting that its primary impact on vIL-6-
induced angiogenesis and tumorigenesis may be due to direct
activation of cellular signal(s) and/or enhancement of vIL-6
signaling. The PI3K/AKT signaling axis plays an important role
in cellular proliferation, cell survival, neovascularization, and
tumor growth. Several components of this signaling axis were
dysregulated in many cancers, including KS [39–42]. Activated
AKT triggers downstream mTOR/p70S6K1 signaling resulting in
the induction of pro-angiogenic factors such as VEGF and b-FGF,
thereby inducing neovascularization to promote tumor growth
[43]. On the other hand, activated AKT phosphorylates and
inactivates GSK-3b to decrease phosphorylation of cyclin D1, and
accordingly, triggering cell proliferation [44]. Notably, PI3K/
AKT axis can be modulated by PTEN, a tumor suppressor which
removes the 39phosphate of PIP3 and attenuates signaling
downstream of the activated PI3K. With regard to relationship
between PI3K/AKT and vIL-6, we found that PI3K/AKT
activated while PTEN/GSK-3b was inactivated in both vIL-6-
producing 4E3 cells and 4E3-mediated tumor tissues from CAM
and nude mice models. Inhibition of PI3K/AKT or overexpres-
sion of PTEN or GSK-3b failed to impair vIL-6 induction of
angiogenesis and tumorigenesis in CAM and nude mice allograft
models, indicating that vIL-6 might exert its biological function
mainly via JAK/STAT signal rather than PI3K/AKT signal
[27,29,30]. Therefore, we concluded that activation of PI3K/
AKT pathway and inactivation of PTEN/GSK-3b signal were
Figure 8. Activation of PI3K/AKT pathway is required for promotion of vIL-6-induced tumorigenesis by Tat in nude mice. (A) Tat
augments vIL-6-induced phosphorylation of AKT and GSK-3b in nude mice. Phosphorylation AKT and GSK-3b in tumor tissues from 4E3 and T/V cells
transduced by Tat and Mock in nude mice were analyzed by Western blot. (B) Plot of the volume of the tumors. 4E3 cells were transfected by the
AKT-DN and its control plasmid pSRa for 24 hours and followed by Tat or Mock transduction for another 24 hours. Cells were injected s.c. into the left
flank of the mice. The animals were monitored every day for the appearance of tumors until 30 days. Tumor size was estimated by two-dimensional
caliper measurement. The results are expressed as the mean 6 SD (n = 5). *P,.05 and **P,.01 for Student’s t-test versus Tat+AKT groups,
respectively. gP,.05 and ggP,.01 for Student’s t-test versus Mock+pSRa groups, respectively. ns, not significant, t-test. (C) Column diagram of
average tumor weight. Tumor-bearing mice were killed at day 30 after injections, and tumors were removed and weighed. Data reflect the mean 6
SD. (D) Inhibition of AKT activity abolished the promoted effect of Tat on phosphorylation of GSK-3b by vIL-6. 4E3 cells were treated as in (B). The
phosphorylation level of GSK-3b in tumor tissues of nude mice was analyzed by Western blot. (E) Plot of the volume of the tumors. 4E3 cells
transduced with Tat or Mock were injected s.c. into mice for allograft formation. The mice received the treatments by intraperitoneal injection of
LY294002 (the detailed procedure seen in Methods). The results are expressed as the mean 6 SD (n = 5). *P,.05 and **P,.01 for Student’s t-test
versus Tat+LY294002 groups, respectively. gP,.05 for Student’s t-test versus Mock+DMSO groups, respectively. (F) Column diagram of average
tumor weight. Tumor-bearing mice were killed at day 40 after injections, and tumors were removed (Top) and weighed. Data reflect the mean 6 SD
(Bottom).
doi:10.1371/journal.pone.0053145.g008
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likely not the main cause of vIL-6-induced angiogenesis and
tumorigenesis.
Although Tat could activate PI3K/AKT-dependent survival
pathways in KS cells [45], in this study, we showed that in Tat-
transduced vIL-6-expressing cells, inhibition of PI3K/AKT and
overexpression of PTEN or GSK-3b signal efficiently suppressed
the enhanced effect of Tat on vIL-6-induced angiogenesis and
tumor development in vivo. Moreover, the PI3K inhibitor
LY294002 greatly impaired the ability of Tat to promote vIL-6-
induced tumorigenesis in allograft model. These data illustrated
that Tat enhanced vIL-6-induced angiogenesis and tumorigenesis
by regulating PI3K/PTEN/AKT/GSK-3b pathway. Therefore,
PI3K/AKT may represent an attractive therapeutic target for
patients with AIDS-related KS. Besides PTEN/AKT signaling
axis, Tat can also activate other multiply cellular signaling
pathway [7,9,10,46]. Thus, additional mechanism by which Tat
regulates vIL-6-induced angiogenesis and tumor growth remains
possible.
Supporting Information
Figure S1 Schematic diagram for generation of stable
transfectants expressing vIL-6, including NIH3T3-de-
rived KS-like cell clones expressing vIL-6 and endothe-
lial cell clones expressing vIL-6.
(EPS)
Figure S2 ELISA for CAT in 4E3, E6, and their
corresponding control cells transfected with pTZIII-
CAT and followed by lentiviral Tat transduction (A) or
soluble Tat treatment (B) for 48 hours. CAT protein
expression was quantitated by ELISA. Results presented were
from three independent experiments performed in triplicate.
(EPS)
Figure S3 Tat augments vIL-6-induced tumorigenesis,
leading to VEGF, b-FGF and Cyclin D1 expression in
CAM model. (A) Immunohistochemical staining analysis of the
expression levels of VEGF, b-FGF, and cyclin D1 in tumor tissues
from Tat-transduced 4E3 cells. The representative pictures were
shown (original magnification,6400). (B) H&E staining analysis
of histological features in tumor tissues from AKT-DN-transfected
4E3 cells followed by Tat transduction in the CAM model. The
representative pictures were shown (original magnification,6400).
Arrowheads point to hemorrhagic foci. (C) Immunohistochemical
staining analysis of the expression levels of VEGF, b-FGF, and
cyclin D1 in tumor tissues from AKT-DN-transfected 4E3 cells
followed by Tat transduction in the CAM model. The represen-
tative pictures were shown (original magnification,6400).
(TIF)
Figure S4 Tat augments vIL-6-induced tumorigenesis,
leading to VEGF, b-FGF and Cyclin D1 expression in
nude mice. (A) Immunohistochemical staining analysis of the
expression level of VEGF, b-FGF, and cyclin D1 in nude mice
tumor tissues from Tat-transduced 4E3 cells. The representative
pictures were shown (original magnification,6400). (B) Quanti-
fication of results in (A).
(EPS)
Figure S5 AKT is involved in vIL-6-induced tumorigen-
esis promoted by Tat in nude mice. (A) H&E staining
analysis of histological features in tumor tissues from AKT-DN-
transfected 4E3 cells followed by Tat transduction in the nude
mice. The representative pictures were shown (original magnifi-
cation, 6200). Arrowheads indicate hemorrhagic foci. (B)
Immunohistochemical staining analysis of the expression levels
of VEGF, b-FGF, cyclin D1, and SMA in tumor tissues from
AKT-DN-transfected 4E3 cells followed by Tat transduction in
the nude mice. The representative pictures were shown (original
magnification,6400). (C) Quantification of results in (B).
(TIF)
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